SHMT2 and glioblastoma: Moreover, SHMT2 and GLDC have been shown to antagonize the activity of PKM2 and reduce oxygen consumption in glioblastoma multiforme (GBM), thereby driving a survival advantage by reprogramming the metabolic state of the tumor (Kim et al., 2015).